peripheral arterial disease
in review
6 min read
Updated 2026-10-19
PAD is a marker of systemic atherothrombosis: MACE risk dominates, limb loss is the minority outcome. Diagnose with ABI <0.9 (TBI when ABI >1.4 from calcified vessels). Symptomatic PAD → rivaroxaban 2.5 mg BID + ASA if bleeding risk is low (especially with high-risk limb or comorbidity), otherwise single antiplatelet (clopidogrel preferred, weak). Asymptomatic PAD → no antithrombotic for the limb, no revascularisation. Every patient: smoking cessation, maximally tolerated statin with add-on to threshold, ACEi/ARB for hypertension, SGLT2i if diabetic, supervised walking for claudication. No screening for CAD or carotid disease.
antithrombotic choice
PAD occlusions are largely thrombotic, not just plaque progression (“athero-thrombo-embolism”) → dual pathway inhibition (low-dose factor Xa inhibitor + platelet inhibitor) reduces both MACE and limb events where antiplatelets alone fall short.
flowchart TD
A[Lower extremity PAD] --> B{Symptomatic or prior revascularisation/amputation?}
B -- No: isolated asymptomatic --> C[No antithrombotic for PAD<br/>treat CAD/stroke indications if present]
B -- Yes --> D{Needs full-dose OAC for AF/VTE?}
D -- Yes --> E[OAC alone<br/>add antiplatelet only if coronary or peripheral event <1 year]
D -- No --> F{Bleeding risk}
F -- High --> G[SAPT: clopidogrel 75 mg, weak preference, or ASA]
F -- Low --> H{High-risk limb or comorbidity?}
H -- Yes --> I[Rivaroxaban 2.5 mg BID + ASA 80–100 mg]
H -- No --> J[Rivaroxaban 2.5 mg BID + ASA, or SAPT<br/>shared decision]
I -. rivaroxaban contraindicated .-> K[DAPT: ASA + clopidogrel or ticagrelor]
- High-risk limb: prior revascularisation, amputation, rest pain, ischaemic ulcer. High-risk comorbidity: polyvascular disease, diabetes, HF, renal insufficiency
- Benefit scales with risk: in COMPASS PAD subgroups, MACE + MALE ARR 4.4–5.2% with high-risk limb or comorbidity vs ≈1% with neither; major bleeding ARI <1%
- Rivaroxaban 2.5 mg BID avoid: strong CYP3A4/P-gp interactors, stroke <1 month, any prior haemorrhagic stroke, eGFR <15. Severe HF (NYHA III–IV, LVEF <30%) was excluded from COMPASS but use is reasonable if otherwise indicated
- Rivaroxaban 2.5 mg BID is not anticoagulation for AF or VTE
- Full-dose OAC added to antiplatelet for stable PAD → no limb or MACE benefit, ~3.4× life-threatening bleeding (WAVE (2007)) → recommended against
- Clopidogrel over ASA as SAPT is a weak CCS recommendation, from the PAD subgroup of CAPRIE (1996); Thrombosis Canada treats ASA 81 mg as standard and clopidogrel as the alternative (ASA intolerance, possibly slightly better). Ticagrelor no better than clopidogrel in PAD (EUCLID (2017))
- Recent coronary revascularisation (<1 year) → antiplatelet regimen per ACS/PCI guidance → post-MI care; AF + vascular disease → antithrombotic therapy in AF with CAD
after revascularisation
| setting | regimen |
|---|---|
| elective endovascular | rivaroxaban 2.5 mg BID + ASA 80–100 mg (strong); ± clopidogrel ≤30 days for complex stenting |
| elective open (bypass) | rivaroxaban 2.5 mg BID + ASA 80–100 mg (strong) |
| endovascular, rivaroxaban not possible | DAPT (ASA + clopidogrel) ≥1 month (CCS; Thrombosis Canada 1–3 months) |
| open, rivaroxaban not possible | SAPT or VKA; VKA favoured for high-risk autologous vein grafts (poor/long conduit, poor runoff, prior failed bypass) |
| urgent/emergent (acute limb ischaemia) | any of: full-dose OAC + SAPT, rivaroxaban 2.5 mg BID + ASA ± short clopidogrel, or DAPT (weak). High re-thrombosis + low bleeding risk → OAC + SAPT |
- VOYAGER PAD (2020): rivaroxaban + ASA vs ASA after revascularisation → MACE + MALE HR 0.85, driven by ↓acute limb ischaemia; ↑ISTH major bleeding, no excess ICH or fatal bleeding. Clopidogrel >30 days → ↑major bleeding
- Continue rivaroxaban + ASA long term after revascularisation (prior revascularisation = high-risk limb)
- Periprocedural: hold rivaroxaban 2.5 mg 12–24 h; clopidogrel 5–7 days; ASA continued for low-bleeding-risk procedures → periprocedural anticoagulation
diagnosis
- Classic claudication (exertional calf cramp, reproducible distance, relieved within 10 min of rest) in only 5–10% of PAD; most are atypical or asymptomatic
- Differential: spinal stenosis, neuropathy, radiculopathy, hip/knee arthritis, Baker cyst, chronic compartment syndrome, venous claudication, popliteal entrapment
- CLTI: ischaemic rest pain, ulcer or gangrene. 1-year mortality ≈22% and major amputation ≈22% without revascularisation
ABI and TBI
ABI = higher ankle systolic pressure (DP or PT) ÷ higher brachial systolic pressure, per leg.
| result | meaning |
|---|---|
| ABI <0.9 | PAD (sens ≈61%, spec ≈92%) |
| ABI >1.4 | non-compressible (medial calcification: diabetes, CKD, age) → unreliable → TBI, tibial waveforms ± TcPO₂ |
| TBI <0.6 | PAD (digital arteries usually spared from calcification) |
- Symptomatic → confirm with ABI and/or TBI (strong)
- Asymptomatic >50 with risk factors (smoking, diabetes) → ABI screening suggested (weak); no population-wide screening (strong, against)
- Patients with PAD → no routine screening for asymptomatic CAD or carotid stenosis (weak, against): management is identical whichever bed is diseased
- Arm-to-arm BP difference → use the higher arm for BP management
risk factor management
| target | recommendation |
|---|---|
| smoking | cessation (strong): counselling + varenicline, combination NRT, bupropion; e-cigarettes in selected patients. Ask at every visit |
| lipids | statin-indicated by definition → max tolerated statin; add ezetimibe and/or PCSK9i if LDL ≥1.8, non-HDL ≥2.4 or apoB ≥0.7 g/L (strong). PCSK9i first if far above threshold. TG 1.5–5.6 on statin → icosapent ethyl → dyslipidaemia |
| BP | ACEi or ARB first line (strong). Targets → hypertension. Caution if SBP <110 (↑MACE and MALE). Beta-blockers not contraindicated |
| diabetes | SGLT2i (strong) — no amputation signal with empagliflozin or dapagliflozin; canagliflozin signal unresolved → SGLT2 inhibitors. GLP-1 RA or DPP-4i reasonable (weak). Tight glycaemic control: weak evidence |
claudication and revascularisation
- Supervised exercise first line (strong): walking preferred; ≥2 sessions/week of ≥30 min for ≥12 weeks; walk to moderate–severe claudication (3–4/5), rest, repeat. Home/community structured programme if supervised unavailable (strong). Then walk ≥30 min ≥3×/week to maintain benefit
- Cilostazol unavailable in Canada; pentoxifylline, carnitine and chelation not recommended
- Claudication natural history: 2–3%/year progress to CLTI, amputation ≤1%/year → revascularisation only for lifestyle-limiting symptoms after failed exercise + OMT, with acceptable risk (weak). Early intervention does not change natural history
- Asymptomatic PAD → no revascularisation (strong)
- CLTI → urgent vascular surgery referral (strong); debride/minor amputation first if deep infection or wet gangrene; primary major amputation if non-reconstructable, non-ambulatory, sepsis or short life expectancy
- Acute limb ischaemia → emergent IV heparin + vascular surgery; exclude cardioembolic source to set long-term antithrombotic
| favours endovascular | favours open |
|---|---|
| focal aortoiliac or femoropopliteal disease | diffuse aortoiliac or infrainguinal disease |
| claudication indication | common femoral or profunda disease (endarterectomy) |
| no adequate vein, prohibitive surgical risk | adequate vein conduit |
| expected survival <2 years | survival >2 years, failed endovascular |
- Bypass: autologous vein over prosthetic (strong); no femoral–tibial bypass for claudication (strong, against)
- No endovascular therapy in the common femoral or profunda (strong, against) → endarterectomy or hybrid
pre-op risk for vascular surgery
- RCRI underestimates MACE in vascular surgery → not recommended (strong, against). Use VSG-CRI or INFRA VQI-CRI for cardiac risk, frailty (mFI ≥0.25 or functional dependence) for 30-day mortality
- Pre-op BNP or NT-proBNP suggested (weak). NT-proBNP ≥300 ng/L or BNP ≥92 ng/L → ≈22% 30-day death/MI → consider post-op monitoring
- Emergency revascularisation is not delayed for risk assessment
Prepared 2026-10-19. Not yet verified — check every number against the sources.